Fender, Anke C. http://orcid.org/0000-0003-3965-6165
Kleeschulte, Sonja
Stolte, Svenja
Leineweber, Katja
Kamler, Markus
Bode, Johannes
Li, Na
Dobrev, Dobromir
Funding for this research was provided by:
Ernst und Berta Grimmke Stiftung (3/09)
Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf (n/a)
National Institutes of Health (R01-HL131517, R01-HL136389, R01-HL089598, R01-HL-136389)
Deutsche Forschungsgemeinschaft (Do 769/4-1)
Article History
Received: 8 October 2019
Accepted: 27 December 2019
First Online: 7 January 2020
Compliance with ethical standards
:
: D. Dobrev is a member of the scientific advisory board of OMEICOS Therapeutics GmbH, a company developing small molecules mimicking the effects of omega-3 fatty acids, and of Acesion Pharma, a company developing selective blockers of small-conductance calcium-dependent potassium channels.
: All human and animal studies were approved by the institutional ethics committees and were performed in accordance with the ethical standards laid down by the Declaration of Helsinki.
: All patients gave written informed consent prior to inclusion in the study.